For rheumatologists, instinct says in RA everything’s better with MTX. For tofacitinib, where immunogenicity not an issue, is that actually true? Canadian registry data: maybe no after 36m, low no. ?valid, markups mine Need to see more of this! #ACR21 ABST0827 ⁦@RheumNow⁩ https://t.co/VVwd4SZgVx